[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100633077":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":17,"centralContacts":22,"locations":28,"responsibleParty":45,"collaborators":17,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":17,"eligibilityCriteria":55,"healthyVolunteers":51,"sex":56,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":17,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":69,"overallStatus":72,"whyStopped":17,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Firat University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Exercise","EXPERIMENTAL","Based on current recommendations for individuals with MS, the PRT program lasted 12 weeks and included three sessions per week, each lasting 60-90 min at 60-80% of one-repetition maximum. The training sessions were conducted three times per week over the 12-week period and were supervised by a qualified physiotherapist",[13],"Other: Exercise",{"label":15,"type":16,"description":17,"interventionNames":17},"Control","NO_INTERVENTION",null,[19],{"type":6,"name":9,"description":20,"armGroupLabels":21,"otherNames":17},"According to current clinical guidelines for multiple sclerosis patients, the progressive resistance training (PRT) protocol will be implemented as follows: a 12-week intervention consisting of three supervised 60-90 minutes sessions per week at 60-80% of one-repetition maximum intensity. All training sessions will be conducted under the direct supervision of a certified physiotherapist to ensure proper technique adherence and safety throughout the intervention period",[9],[23],{"name":24,"role":25,"phone":26,"phoneExt":17,"email":27},"Furkan Bilek, PhD","CONTACT","+905442772249","fzt.furkanbilek@gmail.com",[29],{"facility":30,"status":17,"city":31,"state":17,"zip":32,"country":33,"countryCode":17,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"Fırat University","Elâzığ","23100","Turkey (Türkiye)",{"type":35,"coordinates":36},"Point",[37,38],39.22321,38.67431,{"lat":38,"lon":37},[41],{"name":42,"role":25,"phone":43,"phoneExt":17,"email":44},"Mustafa Kaplan, MD Professor","+904242370000","mustafakaplan@firat.edu.tr",{"type":46,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":17,"oldOrganization":17},"PRINCIPAL_INVESTIGATOR","Furkan Bilek","Principal Investigator","100633077","impact-of-exercise-training-on-serum-glial-fibrillary-acidic-protein-gfap-brain-volumetry-and-functional-outcomes-in-multiple-sclerosis-100633077",false,"NCT07521995","Impact of Exercise Training on Serum Glial Fibrillary Acidic Protein (GFAP), Brain Volumetry, and Functional Outcomes in Multiple Sclerosis","The Effect of an Exercise Intervention on Serum Glial Fibrillary Acidic Protein (GFAP), Brain Volumetry and and Functional Outcomes in Patients With Multiple Sclerosis: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinically confirmed relapsing-remitting multiple sclerosis (RRMS) diagnosis according to revised McDonald criteria (2017)\n* Mild-to-moderate disability (EDSS score 1.0-5.5)\n* No corticosteroid treatment within the previous 3 months\n\nExclusion Criteria:\n\n* Acute MS relapse within 90 days before enrollment\n* Regular participation in structured exercise programs (\\>3 hours\u002Fweek)\n* Comorbid conditions that may limit exercise participation, including significant orthopedic impairments, unstable cardiopulmonary conditions, and other systemic disorders affecting physical activity\n* Standard MRI contraindications (metallic implants, claustrophobia, etc.)\n* Concurrent neurological disorders (other than MS)\n* Initiation or modification of disease-modifying therapy within 6 months\n* Severe spasticity (Modified Ashworth Scale ≥3 in any major muscle group)","ALL","18 Years","65 Years",{"count":60,"type":61},30,"ESTIMATED","INTERVENTIONAL",[64],"NA","This single-blind, randomized controlled trial will employ a two-arm parallel design (exercise group vs. control group) with a 12-week intervention period. Randomization will be implemented using SPSS 25.0 (IBM Corporation, Armonk, NY, USA) to ensure balanced group allocation. All outcome measures will be assessed at baseline and post-intervention.",[67,9,68],"Multiple Sclerosis","Function",[9,70,71],"Glial Fibrillary Acidic Protein","Brain Volume","NOT_YET_RECRUITING","2026-04-03",{"date":75,"type":76},"2026-04-13","ACTUAL",{"date":78,"type":61},"2026-05-01",{"date":80,"type":61},"2026-09-01",{"name":5,"class":6},1]